Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.14 CAD | -1.69% | -0.61% | +25.23% |
Jun. 05 | Aurora Cannabis Introduces Resin Cartridges in Australia | MT |
Jun. 05 | Aurora Cannabis Brief: Unveiling Premium Resin Cartridges in Australia | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.23% | 330M | D+ | ||
+32.81% | 6.06B | B- | ||
-25.27% | 4.11B | C+ | ||
+5.41% | 3.4B | C | ||
-21.39% | 2.81B | B- | ||
-11.93% | 2.31B | - | D+ | |
+44.07% | 1.95B | - | ||
-17.86% | 1.54B | - | - | |
+43.25% | 1.53B | - | ||
-9.38% | 1.51B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACB Stock
- Ratings Aurora Cannabis Inc.